Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​New policy on Aducanumab (AduhelmTM) for Alzheimer disease

July 26, 2022

​Independence Blue Cross (Independence) published new medical policies on July 1, 2022, to further communicate its coverage position on the drug aducanumab (Aduhelm) for the treatment of Alzheimer disease for its Commercial and Medicare Advantage members.

Effective June 7, 2021, the use of Aduhelm is considered experimental/investigational and therefore not covered for all indications, including the treatment of Alzheimer disease, for Independence Commercial members.

Effective April 7, 2022, and in accordance with Medicare, monoclonal antibodies directed against amyloid (including Aduhelm) for the treatment of Alzheimer disease is considered experimental/investigational and therefore not covered, except for Coverage with Evidence Development, for Independence Medicare Advantage members.

For more information, please view the following Independence medical policies:


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.